Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.58 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128714 | 0.98 | DDB1 (0.57) | DDB1CRBNGID4NPC1MEN1 | |
| SCHEMBL317559 | 0.95 | GID4 (0.63) | DDB1CRBNGID4NPC1MEN1 | |
| SCHEMBL21286784 | 0.89 | DDB1 (0.67) | DDB1CRBNGID4NPC1MEN1 | |
| SCHEMBL11534052 | 0.84 | SMN1; SMN2 (0.46) | DDB1CRBNGID4MEN1KMT2A | |
| SCHEMBL318339 | 0.84 | MAPK1 (0.45) | DDB1CRBNGID4MEN1KMT2A | |
| SCHEMBL10109186 | 0.84 | MAPK1 (0.45) | DDB1CRBNGID4MEN1KMT2A | |
| SCHEMBL6404794 | 0.83 | SMN1; SMN2 (0.47) | DDB1CRBNGID4RAB9A | |
| SCHEMBL21452545 | 0.81 | ADCYAP1R1 (0.47) | DDB1CRBNGID4 | |
| SCHEMBL318066 | 0.81 | MAPK1 (0.56) | DDB1CRBNNPC1MEN1KMT2A | |
| SCHEMBL16937274 | 0.81 | DDB1 (0.52) | DDB1CRBNGID4NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | SYNPHATEC (SHANGHAI) BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-01 | — | — | US | disclosed |
| EP-4339189-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-113527130-B | Synthesis method of alpha-amide, alpha-aryl quaternary carboketone compound | 兰州大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-113234036-B | NMDA receptor antagonists and uses thereof | 斯莱普泰(上海)生物医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022237849-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | 中国科学院上海有机化学研究所 | 2022-11-17 | — | — | WO | disclosed |
| CN-113527130-A | Synthetic method of alpha-amide and alpha-aryl quaternary carbon ketone compound | 兰州大学 | 2021-10-22 | — | — | CN | disclosed |
| CN-113234036-A | NMDA receptor antagonists and uses thereof | 中国科学院上海有机化学研究所 | 2021-08-10 | — | — | CN | disclosed |
| CN-111233599-B | Aromatic ring ortho-iodoalkanone and synthetic method and application thereof | 兰州大学 | 2021-07-20 | — | — | CN | disclosed |
| US-20210171487-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JIANHE PHARMACEUTICAL & TECHNOLOGY CO. LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
| US-5451600-A | FOR TREATMENT OF INFLAMMATORY DISEASES AND TRAUMA INDUCED INFLAMMATION | HOFFMANN-LA ROCHE INC. (US) | 1995-09-19 | — | — | US | disclosed |
| WO-1995017393-A1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-29 | — | — | WO | disclosed |
| EP-0033156-B1 | 1-PHENYL-2-CYCLOHEXENE-1-ALKYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-10-17 | — | — | EP | disclosed |
| US-4448991-A | ANALGESICS | HOFFMANN-LA ROCHE INC. (US) | 1984-05-15 | — | — | US | disclosed |
| US-4337341-A | 4a-Aryl-octahydro-1H-2-pyrindines | ELI LILLY AND COMPANY (US) | 1982-06-29 | — | — | US | disclosed |
| US-4336268-A | Cyclohexene derivative analgesics | HOFFMANN-LA ROCHE INC. (US) | 1982-06-22 | — | — | US | disclosed |
| US-4287212-A | USEFUL AS ANALGESICS AND DIURETICS | AMERICAN HOECHST CORPORATION (US) | 1981-09-01 | — | — | US | disclosed |
| EP-0033156-A2 | 1-Phenyl-2-cyclohexene-1-alkylamine derivatives, process for their preparation and medicines containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-08-05 | — | — | EP | disclosed |
| US-4141893-A | Decahydrocyclopent[c]azepines | ELI LILLY AND COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
| US-4141894-A | ANALGESICS, ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | GRIN2B, GRIN1, GRIN3A | DDB1 3579/4885CRBN 4067/4885GID4 1968/4885 |
| US-20210171487-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, PAH, COMT | DDB1 4837/4885CRBN 1390/4885GID4 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.